Codexis, Inc., a protein engineering company, has completed the third and final wave in the transfer of its CodeEvolver protein engineering platform technology to GlaxoSmithKline. Codexis expects to receive a $7.5 million payment from GSK for completion of this milestone in 2Q16.   “We are delighted to have successfully completed the first full transfer of our CodeEvolver technology platform under a licensing agreement,” said Codexis president and chief executive officer John Nicols. “I am ver...